source
- Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B dealServier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
- Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy supportOrphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…